Trial record 1 of 3 for:    PKD Core
Previous Study | Return to List | Next Study

PKD Clinical and Translational Core Study (PKD Core)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by University of Maryland
Information provided by (Responsible Party):
Terry Watnick, University of Maryland Identifier:
First received: May 23, 2013
Last updated: June 5, 2013
Last verified: June 2013

May 23, 2013
June 5, 2013
March 2013
June 2015   (final data collection date for primary outcome measure)
Renal volume by MRI [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Calculations of the volume will be based on summation of the products of the area measurements of the kidneys and/or liver and slice thickness. A region-based signal threshold method will be applied to calculate total cyst volume, and the remaining parenchymal renal and hepatic volume.
Same as current
Complete list of historical versions of study NCT01873235 on Archive Site
Quality of Life: [ Time Frame: Annually up to 4 years ] [ Designated as safety issue: No ]
Self-reported Quality of Life (pain, anxiety, depression, physical activity, fatigue).
Same as current
Hospitalizations [ Time Frame: Annually up to 4 years ] [ Designated as safety issue: No ]
Same as current
PKD Clinical and Translational Core Study
The Baltimore Polycystic Kidney Disease Clinical and Translational Core Study

Advances in our understanding of the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) have opened up possibilities of new therapies to prevent disease progression. High quality clinical investigations in patients with ADPKD, however, pose significant challenges to investigators including limited access to patients with ADPKD,insufficient guidance by experienced investigators and lack of resources to conduct these studies.

The Polycystic Kidney Disease Research Clinical and Translational Core (P30) aims to establish an infrastructure that will assist investigators in designing and conducting highest quality clinical and translational research focused on a diverse group of patients with ADPKD.

Objective 1: To establish a Mid-Atlantic cohort of ADPKD patients (N=200) with baseline clinical phenotyping performed at the General Clinical Research Unit of the University of Maryland School of Medicine.

Objective 2: To establish a state-of-the-art biobank of specimens from the ADPKD cohort including serum, plasma,urine and DNA.

Objective 3: To develop a collaborative network of physicians and practices in the Mid-Atlantic region who will contribute to the ADPKD cohort and will be willing to refer patients for future studies and trials.

Objective 4: To establish a web-based registry of ADPKD patients in the Mid-Atlantic area.

Not Provided
Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
4 Years
Retention:   Samples With DNA

Plasma, serum,urine, and DNA will be collected at the baseline visit and stored in a biorepository.

Non-Probability Sample

Adults with diagnosed Polycystic Kidney Disease

Polycystic Kidney Disease
Not Provided
Main Cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Age 18 and older
  • ADPKD confirmed by genetic testing or ultrasound criteria using modified Ravine criteria: with family history:several cysts per kidney (3 by sonography, 5 if by computerized tomography or MRI)without family history: 10 cysts (by any radiologic method) per kidney and exclusion of other cystic kidney diseases
  • Ability to provide written informed consent prior to initiation of any study procedures and the ability in the opinion of the investigator to comply with all requirements of the study
  • Glomerular Filtration Rate (GFR) less than 20ml/min/1.73m2

Exclusion Criteria:

  • End Stage Renal Disease or presently on dialysis or a prior kidney transplant
  • Inability to undergo MRI due to any reason including presence of pacemaker and defibrillator
  • Allergy to contrast or iodine
  • Pregnant, lactating, or intention to get pregnant in next 6 weeks
  • Another systemic disease such as diabetes or lupus
  • Life expectancy less than 2 years
  • Current participation in a drug treatment trial
  • Non English speaking
18 Years and older
Contact: Charalett E Diggs, RN, MSN 410-328-0207
Contact: Karkleen Schuhart 410-328-3727
United States
Terry Watnick, University of Maryland
University of Maryland
  • National Institutes of Health (NIH)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Terry J Watnick, MD University of Maryland
University of Maryland
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP